Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimonabant in Cervical Spinal Cord Injury
NCT07843108Phase 2Active, not recruiting
- Sponsor
- Sinfatin
- Start
- May 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rimonabant in cervical spinal cord injury, sponsored by Sinfatin. Primary endpoint: Graded Redefined Assessment of Strength, Sensibility and Prehension at day 120. Started May 2026; status: active, not recruiting.
02
Drugs
rimonabant
03
Conditions
cervical spinal cord injury
Beyond the preview
Go deeper on NCT07843108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07843108.